Zhejiang East-Asia Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang East Asia Pharmaceutical Co., Ltd. was established in 1998 and headquartered in Taizhou City, Zhejiang Province. It has been awarded titles such as "National High tech Enterprise", "Zhejiang Patent Demonstration Enterprise", and "Top Ten Enterprises in Management Innovation in Taizhou City". We have also established provincial-level research institutes and provincial-level enterprise technology centers. We have undertaken multiple national torch program projects and have applied for more than 30 national invention patents. We have obtained 27 national invention patent authorizations and 1 PCT international patent. East Asia has established an integrated pharmaceutical base in Sanmen, Zhejiang, Linhai, and Jiujiang, Jiangxi, which is mainly engaged in cardio cerebrovascular, anti senile dementia and disability, digestive system, diabetes neuropathy, and antigenic microorganisms (including β- Raw materials and intermediates for lactam antibiotics, carbapenem semi synthetic antibiotics, synthetic antibiotics, antifungal, antiviral infections, central nervous system, and other fields. Multiple products of the company have passed the new version of CGMP certification, European Union (EDQM) certification, and Japan's Ministry of Health and Welfare (PMDA) certification. We have established long-term cooperative relationships with customers from more than ten countries and regions such as Europe, America, and Southeast Asia, and our product sales network covers more than 50 countries and regions worldwide. East Asia has a modern research and development center in the Shanghai International Medical Park, and has established a research team mainly composed of doctoral and master's degrees, specializing in cutting-edge information and technology research and development, providing a platform for the company's sustained development and market competition. The company adheres to the policy of "quality responsibility, caring for life; sincere and trustworthy, committed to development; health mission, technology escort; commitment to society, gratitude and feedback", and is a "Shanyuan" pharmaceutical enterprise that is based on goodness and can only have a long history. We are mainly engaged in the production of raw materials, tablets, granules, and capsules. Our main products include: ofloxacin, levofloxacin, loratadine, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, tiopronin, levofloxacin lactate, epalastat, donepezil hydrochloride, thiaconazole, etc. |
| Headquarter | Taizhou |
| Establish Date | 2/6/1998 |
| Listed Code | 605177.SH |
| Listed Date | 11/25/2020 |
| Chairman | Chi Zhengming. |
| CEO | Chi Cheng. |
| Website | www.eapharm.net |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
